All News

Personalized medicine, which targets individualized treatment and care based on personal and genetic variations, holds much promise for the pharmaceutical industry.

New pharma supply chains, where chill control and traceability challenges will be far more critical, will emerge over the next decade, So it’s time, argues Julian Mosquera, for the industry to upgrade its capabilities.

Even though Roche-owned Genentech wasn’t required to run costly corrective advertisements following an FDA Untitled Letter on Boniva last January, the company has done so anyway.

The 2011 Edelman Health Barometer suggests that-in the same way that we spread colds, diseases, and other illnesses from person to person-good health and healthy behaviors can also be spread. Can pharma play a pivotal role in the good-health epidemic?

One of the few positive notes struck in this week’s 30th Annual J.P. Morgan Healthcare Conference (held in San Francisco) was the announcement by Kevin Willsey, J.P. Morgan’s co-head of investment banking for North America, that the U.S. economy would grow 2.5 percent in 2012

Estimates of what it takes to deliver a compound to market are more than an academic exercise - such data has an increasingly important on-the-ground impact on industry revenues, because if you cannot justify your costs how do you expect to prevail on price?

Outgoing CEO Michael McCallister said one of Humana’s primary strategies going forward is to keep patients out of hospitals and other healthcare institutions, when possible.

Long before the current debate on health care started, there was a different war brewing. For decades, people have been fighting over which program and plan is best: healthcare provided to government workers, military personnel or civilians?

In 2011, the patient’s clout as a stakeholder was firmly established, as reflected in several industry conferences. What’s next for the patient in 2012?

Big Pharma received a nod in the UK’s New Year’s Honours List this week when a knighthood was duly bestowed upon GSK’s Andrew Witty - making him ‘Sir Andrew’ to you and me. For once, though, receiving such an honor did not exactly place him in totally exalted company.

Those in favor of a less is more approach to FDA social media guidelines got what they wanted for the holidays: a trim, 15-page document on how to respond to unsolicited off-label comments

Industry Forecast 2012 : Bridging the Divide

RaQualia's New Spin on the Startup

Some of the most creative and influential graphic designers and illustrators did time in pharma marketing.

With conflicting lower court decisions over whether pharmaceutical sales reps should be paid for overtime, the Supreme Court has agreed to settle the matter. The court will hear the case brought by two former GSK reps that were denied their overtime claim by a Circuit Court.

PhamExec Global Digest 2012

June 2011 BPA Statement

Red Light on the Access Autobahn

We ask three managers building Greenfield plants to rationalize and defend their decisions

How is the world's dedicated pharma leader going to improve its positioning in Russia? Pfizer's country manager Christian Holmer comments.

Five years of legislation in the Russian pharmaceutical industry

Foreign player? Choose a local partner

Know your strengths, then expand

Russia had been a country in flux-monetary crises, corruption scandals, oil surpluses, etc. But no multinational should be scared off by the market anymore, not with its economy on the verge of breaking out.

The triple bottom line

A celebration of achievement

If high prices that lower access are attributable to a flawed R&D model, can industry embrace delivering better results at lower costs.

Pharm Exec's 2011 Emerging Leaders celebration convened Oct. 6 in New York.

Over 25 years the Rx Club Show has reflected dramatic technological changes in advertising. But, as always, the subject comes first, the medium second. So where did the accolades go this year?